Cargando…

Gosha-Jinki-Gan Improved Erectile Dysfunction Caused by Anti-Cancer Agent Oxaliplatin by Decreasing Transcriptional Expression of Phosphodiesterase-5 in Rats

BACKGROUND: A platinum-containing anti-cancer agent, oxaliplatin (L-OHP), is known to induce peripheral neuropathy, including erectile dysfunction (ED) as a side effect, while Gosha-jinki-gan (GJG) is a traditional Japanese herbal medicine mainly used for peripheral neuropathy. AIM: To investigate t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kataoka, Tomoya, Kawaki, Yuto, Kito, Yohei, Suzuki, Jun, Mori, Taiki, Hotta, Yuji, Sanagawa, Akimasa, Kawade, Yoshihiro, Maeda, Yasuhiro, Furukawa-Hibi, Yoko, Kimura, Kazunori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023251/ https://www.ncbi.nlm.nih.gov/pubmed/35065470 http://dx.doi.org/10.1016/j.esxm.2021.100484

Ejemplares similares

Gosha-Jinki-Gan Recovers Spermatogenesis in Mice with Busulfan-Induced Aspermatogenesis
por: Qu, Ning, et al.
Publicado: (2018)

Gosha-jinki-gan (a Herbal Complex) Corrects Abnormal Insulin Signaling
por: Qin, Bolin, et al.
Publicado: (2004)

Clinical efficacy and tolerability of Gosha-jinki-gan, a Japanese traditional herbal medicine, for nocturia
por: Yagi, Hiroshi, et al.
Publicado: (2015)

Effect of Gosha-Jinki-Gan on Levels of Specific mRNA Transcripts in Mouse Testes after Busulfan Treatment
por: Qu, Ning, et al.
Publicado: (2020)

Effect of High Testosterone Levels on Endothelial Function in Aorta and Erectile Function in Rats
por: Kataoka, Tomoya, et al.
Publicado: (2022)

Evaluating the Effects of Low Carbohydrate and High Protein Diet on Erectile Function in Rats
por: Kataoka, Tomoya, et al.
Publicado: (2022)

Clinical efficacy and tolerability of two Japanese traditional herbal medicines, Hachimi-jio-gan and Gosha-jinki-gan, for lower urinary tract symptoms with cold sensitivity
por: Yagi, Hiroshi, et al.
Publicado: (2015)

Live-Imaging Analysis of Target Vessels and Nitric Oxide Production Associated with Gosha-Jinki-Gan and Keishi-Bukuryo-Gan: Two Herbal Preparations with Clinically Proven Blood Flow-Improving Effects but with Different Traditional Clinical Indicative Patterns
por: Hirayama, Aki, et al.
Publicado: (2022)

Influence of anticancer agents on sexual function: An in vivo study based on the US FDA Adverse Event Reporting System
por: Kataoka, Tomoya, et al.
Publicado: (2021)

The Relationship between Changes in Serum Element Concentrations and Pathological Condition and Disease Status in Japanese Multiple Myeloma Patients: A Pilot Study and Literature Review
por: Yamamoto, Yuko, et al.
Publicado: (2023)

Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System
por: Sanagawa, Akimasa, et al.
Publicado: (2018)

A review of experimental techniques for erectile function researches and development of medical technology using animal erectile dysfunction models in sexual and reproductive medicine
por: Kataoka, Tomoya, et al.
Publicado: (2023)

Outcomes of the implementation of the computer-assisted HBView system for the prevention of hepatitis B virus reactivation in chemotherapy patients: a retrospective analysis
por: Sanagawa, Akimasa, et al.
Publicado: (2015)

Enhancement of the RhoA/Rho kinase pathway is associated with stress‐related erectile dysfunction in a restraint water immersion stress model
por: Mori, Taiki, et al.
Publicado: (2021)

Changes in zinc and manganese concentrations in cisplatin-induced acute kidney injury
por: Yamamoto, Yuko, et al.
Publicado: (2023)

Efficacy of a Red-Light Controllable Nitric Oxide Releaser for Neurogenic Erectile Dysfunction: A Study Using a Rat Model of Cavernous Nerve Injury
por: Mori, Taiki, et al.
Publicado: (2023)

Clinical Usefulness of the “MN Criteria” - the Clostridioides difficile Infection Severity Scoring System - in the Japanese Setting
por: Asaoka, Minami, et al.
Publicado: (2022)

Go-sha-jinki-Gan (GJG) ameliorates allodynia in chronic constriction injury model mice via suppression of TNF-α expression in the spinal cord
por: Nakanishi, Miho, et al.
Publicado: (2016)

Effect of Late Androgen Replacement Therapy on Erectile Function Through Structural Changes in Castrated Rats
por: Kataoka, Tomoya, et al.
Publicado: (2021)

Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study
por: Kondo, Masahiro, et al.
Publicado: (2020)

The phosphodiesterase 5 inhibitor tadalafil has renoprotective effects in a rat model of chronic kidney disease
por: Tomita, Natsumi, et al.
Publicado: (2020)

Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors
por: Al-Ameri, H, et al.
Publicado: (2009)

Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction
por: Giannitsas, Konstantinos, et al.
Publicado: (2008)

Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction
por: Sung, Hyun Hwan, et al.
Publicado: (2012)

The devil is in the details: an analysis of the subtleties between phosphodiesterase inhibitors for erectile dysfunction
por: Smith-Harrison, L.I., et al.
Publicado: (2016)

Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction
por: Moschos, Marilita M, et al.
Publicado: (2016)

The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews
por: Pyrgidis, Nikolaos, et al.
Publicado: (2021)

Light-controlled relaxation of the rat penile corpus cavernosum using NOBL-1, a novel nitric oxide releaser
por: Hotta, Yuji, et al.
Publicado: (2016)

Endothelial Dysfunction, Erectile Dysfunction and Phosphodiesterase 5 Inhibitors. An Update of the Current Data and Future Perspectives
por: Konstantinopoulos, Angelis, et al.
Publicado: (2007)

Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons
por: Ferguson, James E., et al.
Publicado: (2013)

A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil
por: Evans, Jeffery D, et al.
Publicado: (2015)

Effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analyses
por: Pyrgidis, Nikolaos, et al.
Publicado: (2021)

Toward a new ‘EPOCH’: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction
por: Sadovsky, R, et al.
Publicado: (2009)

Phosphodiesterase type 5 inhibitors for the treatment of post-nerve sparing radical prostatectomy erectile dysfunction in men
por: Li, Jinhong, et al.
Publicado: (2014)

Alterations in the phosphodiesterase type 5 pathway and oxidative stress correlate with erectile function in spontaneously hypertensive rats
por: He, Weixiang, et al.
Publicado: (2020)

Inflammatory biomarkers may predict response to phosphodiesterase type 5 inhibitor treatment in patients with erectile dysfunction
por: Kilic, Metin, et al.
Publicado: (2023)

Oral L-citrulline and Transresveratrol Supplementation Improves Erectile Function in Men With Phosphodiesterase 5 Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Crossover Pilot Study
por: Shirai, Masato, et al.
Publicado: (2018)

Molecular Properties of New Enzyme Rhodopsins with Phosphodiesterase Activity
por: Sugiura, Masahiro, et al.
Publicado: (2020)

Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
por: Savas, Murat, et al.
Publicado: (2010)

Let’s rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomy
por: Kim, Su Jin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_824gpsij2m863c94tf5b62rpmp